Drug intelligence / Profile preview

CLR 225

Development stage: Preclinical
Lead developer: Cellectar Biosciences
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CLR 225 is an investigational radiopharmaceutical developed by Cellectar Biosciences. It is part of a platform of alpha- and Auger-emitting radioconjugates designed for targeted cancer therapy. CLR 225 utilizes a radioisotope, likely actinium-225 (Ac-225), to deliver potent radiation directly to tumor cells, aiming to maximize anti-tumor effects while minimizing damage to healthy tissue. The drug is being explored for use in multiple solid tumor indications[1][4]. Its mechanism involves the targeted delivery of alpha particle radiation via a conjugated molecule that selectively accumulates in cancer cells.

Other names: 225Ac-CLR 225

Targets

PS (Phosphatidylserine)

Beyond the preview

Go deeper on CLR 225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLR 225.

Explore the full profile